Perampanel as first line monotherapy for seizure in japan. A single-centre real-world study
- 18.08.2025
- Research
Erschienen in:
- Verfasst von
- Naoki Nakano
- Kouichiro Fujimoto
- Masaharu Miyauchi
- Jun C. Takahashi
- Erschienen in
- Acta Neurologica Belgica | Ausgabe 6/2025
Abstract
Aims
The aim of this study was to examine the efficacy of Perampanel (PER) monotherapy for patients with seizures in a single-centre in Japan. The National Health Insurance began covering PER monotherapy in Japan since January 2020, after which we began using PER as monotherapy for patients with epilepsy at our institute.
Methods
All patients given PER between January 2020 and December 2022 were evaluated in this retrospective study. Treatment outcomes (including the seizure rate and seizure- free status) and patient sex, seizure type, and seizure aetiology were evaluated.
Results
Sixty-three patients (29 females, 34 males) receiving PER monotherapy as the first-line antiseizure medication for epilepsy were evaluated. The age range was 12 to 88 years, with a mean age of 64.5 ± 18.8years. The follow-up period ranged from 194 days to 1004days, with a median of 576 days from PER initiation. A total of 49 patients (77.8%) were seizure free, while the other 14 patients had incomplete seizure control, including 2 patients (3.2%) who had a 75–99% reduction in seizures, 4 patients (6.3%) who had a 50–74% reduction in seizures,8 patients (12.7%) who had a 25–49% reduction in seizures, and no patients with a 0–24% reduction in seizures. The median PER dose was 2 mg (range; 2-8 mg). No patients discontinued PER monotherapy owing to adverse effects such as transient dizziness at initial administration.
Conclusion
Perampanel monotherapy was effective for treating a wide spectrum of seizures, especially seizures related to lesions such as brain tumours, stroke and trauma. Seizure control could be achieved with a minimum dose of PER (2 mg/day).
Anzeige
- Titel
- Perampanel as first line monotherapy for seizure in japan. A single-centre real-world study
- Verfasst von
-
Naoki Nakano
Kouichiro Fujimoto
Masaharu Miyauchi
Jun C. Takahashi
- Publikationsdatum
- 18.08.2025
- Verlag
- Springer International Publishing
- Erschienen in
-
Acta Neurologica Belgica / Ausgabe 6/2025
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993 - DOI
- https://doi.org/10.1007/s13760-025-02865-1
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
